The study aims to assess the outcome of clinical remission and its components among adult patients with severe asthma who initiated mepolizumab between 30 June 2017 and 30 June 2022 in the real-world setting, across three European Union (EU) countries (i.e., France, Germany, and Italy). Findings from this study will present valuable information on the effectiveness of mepolizumab in reducing asthma exacerbations and oral corticosteroids (OCS) use, optimizing/stabilizing lung function, and improving asthma control scores. In addition, the study will provide additional evidence to support and facilitate the use of clinical remission of asthma as the treatment goal for asthma management in real-world clinical settings.